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Dear Editor,
We would like to report the first case of bilateral severe
anterior uveitis secondary to erlotinib. Erlotinib is an
epidermal growth factor receptor (EGFR) inhibitor which
can contain certain cancer cells [1]. It is licensed for use in
patients with non-small-cell lung carcinoma (NSCLC) in
the UK as a secondary treatment for those patients who fail
to respond to standard chemotherapy [2].
Case history
A 63-year-old lady presented to eye casualty with a 5-day
history of bilateral red watery (non-discharging) eyes,
accompanied by photophobia, reduced vision and a dull
ache in both eyes. The best corrected visual acuity (BCVA)
was Snellen acuity of 6/24 in the right eye and 6/12 in the
left. She had been diagnosed with non-small-cell lung
carcinoma (NSCLC) about 9 months previously and had
not responded to standard chemotherapy. Other than the
NSCLC, there was no significant past medical history. She
was commenced on erlotinib (150 mg OD PO) about
6 weeks prior to her presentation to the eye clinic. Her other
medications were loperamide and oxytetracycline. During
the fifth week of erlotinib treatment, she developed dull,
aching, red, watery eyes with reduced vision. At the same
time she also developed diarrhoea, frontal headache, nausea
and mouth irritation.
Ocular examination revealed bilateral severe anterior
uveitis with almost complete posterior synechiae (Fig. 1).
The anterior chamber examination revealed fine keratic
precipitates, cells (3+) and flare (2+). There was no
hypopyon. Fundus examination was unremarkable. There
was no clinical evidence of ocular metastases. She was
treated appropriately with regular topical ocular steroid
(prednisolone acetate 1%) and mydriatic (atropine 1%).
Subsequently the posterior synechiae and the anterior
uveitis resolved after 2 weeks.
In view of the history, it is very likely that the bilateral
anterior uveitis was secondary to the erlotinib. However,
Fig. 1 One of the pupils showing almost complete posterior
synechiae due to anterior uveitis
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